Dasiglucagon + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia
Trial Timeline
Nov 7, 2018 → Jun 24, 2019
NCT ID
NCT03735225About Dasiglucagon + Placebo
Dasiglucagon + Placebo is a phase 1 stage product being developed by Zealand Pharma for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03735225. Target conditions include Hypoglycemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04836273 | Phase 2 | Completed |
| NCT04172441 | Phase 2/3 | Completed |
| NCT03735225 | Phase 1 | Completed |
| NCT03688711 | Phase 3 | Completed |
Competing Products
20 competing products in Hypoglycemia